Neuroscience
Johnson & Johnson Innovative Medicine’s history is closely tied to neuroscience. The very first medication developed by Dr Paul Janssen, our company founder, was for the treatment of schizophrenia. It set us on a path of discovery and development.
Science is only part of the story
You’re not alone: one in five of us will be affected by a mental health disorder in our lifetime1. For those affected and their loved ones, the impact of mental illness is often vast. We are determined to continue increasing our understanding of mental illness to reduce the disability and devastation caused by serious neuropsychiatric and neurodegenerative diseases.
Approximately 8% of Canadian adults will experience major depression at some time in their lives. It’s the leading cause of disability worldwide with high unmet need.
Approximately 1% of Canadians are affected by schizophrenia, a treatable yet complex mental illness that affects how a person thinks, feels, behaves and relates to others. It is believed to be caused by a combination of biological and environmental factors that contribute to its development.2